CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)GlobeNewsWire • 09/28/22
Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR DrugInvestors Business Daily • 09/27/22
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022Business Wire • 09/27/22
Intellia's stock is up 6% on data from an early-stage trial for its Crispr therapyMarket Watch • 09/16/22
If You've Got $5,000, Buying These 5 Top Stocks Right Now Would Be a Genius MoveThe Motley Fool • 09/15/22
CRISPR Therapeutics AG (CRSP) Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/12/22
CRISPR Therapeutics AG (CRSP) Citi 17th Annual BioPharma Conference TranscriptSeeking Alpha • 09/07/22
CRISPR Therapeutics AG (CRSP) Down 16.5% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/07/22
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/08/22